ReviewObesity facts2009
Obesity and polycystic ovary syndrome.
Review in Obesity facts, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.Reproductive biology and endocrinology : RB&E · 2023Pooled it
- Prevalence of Common Gynecological Conditions in the Middle East: Systematic Review and Meta-Analysis.Frontiers in reproductive health · 2021Pooled it
- Ovarian surgery for symptom relief in women with polycystic ovary syndrome.The Cochrane database of systematic reviews · 2017Pooled it
- Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta-analysis.Endocrine journal · 2016Pooled it
- Antidepressants for polycystic ovary syndrome.The Cochrane database of systematic reviews · 2013Pooled it
- Efficacy of an Eastern Healthy Dietary Pattern-modified ketogenic diet in patients with obesity and polyendocrine metabolic ovarian syndrome.Frontiers in endocrinology · 2026Trial
- A Randomized Trial of the Efficacy of Three Weight Loss Diet Interventions in Overweight/Obese with Polycystic Ovary Syndrome.Endocrine, metabolic & immune disorders drug targets · 2024Trial
- Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.Advances in therapy · 2021Trial
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Assessment of nutritional status among rural women of reproductive age group in Wayanad District, Kerala.Journal of family medicine and primary care · 2025Article
- Evaluation of subclinical atherosclerosis in women with polycystic ovary syndrome based on ultra-high-frequency ultrasound and vector flow imaging.Quantitative imaging in medicine and surgery · 2025Article
- Efficacy of probiotics combined with metformin and a calorie-restricted diet in obese patients with polycystic ovary syndrome.Pakistan journal of medical sciences · 2025Article
- Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.F1000Research · 2025Review
- Prevalence of Polycystic Ovary Syndrome (PCOS) and Its Associated Risk Factors among Medical Students in Two Countries.International journal of environmental research and public health · 2024Article
- Impact of Smoking and Obesity on the Selected Peptide Hormones and Metabolic Parameters in the Blood of Women with Polycystic Ovary Syndrome-Preliminary Study.International journal of molecular sciences · 2024Article
- A combination of gliclazide and metformin attenuates obesity-induced polycystic ovary syndrome in female Wistar rats.Heliyon · 2024Article
- Depression and Anxiety in Patients With Polycystic Ovary Syndrome: A Cross-Sectional Study in Saudi Arabia.Cureus · 2024Article
- Review
- Outcome of Gastric Bypass Surgery on Patients with Polycystic Ovary Syndrome: A Review.Journal of clinical medicine · 2023Review
- Polycystic Ovary Syndrome as Metabolic Disease: New Insights on Insulin Resistance.TouchREVIEWS in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women of fertile age. Obesity is encountered in 30-70% of PCOS-affected women, and its presence significantly modifies both clinical and laboratory expression of the syndrome. Obesity increases the risk of co-morbidities associated with PCOS, such as impaired glucose tolerance and type 2 diabetes mellitus, hyperlipidemia and arterial hypertension. The etiopathogenesis of obesity in PCOS has not yet been exactly clarified. There clearly is a vicious circle of abdominal obesity, insulin resistance, and hyperadrogenemia. Differences in ghrelin and neuropeptide Y levels between PCOS patients and those with simple obesity were also described. Weight loss is the first choice recommendation for the treatment of clinical manifestations of PCOS, such as menstrual cycle irregularities, infertility or hirsutism. However, the best treatment approach in obese PCOS patients remains to be defined. Studies concerning different weight loss regimens, antiobesity drugs, bariatric surgery, insulin sensitizers, and hormonal therapy are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.